“Expanded 2026 ADA Guidance on SGLT2i in CKD Starting at EGFR ≥20 and Combining With a Nonsteroidal MRA”. Diabzen 4, no. 17 (July 7, 2026): 34–35. Accessed September 17, 2026. https://www.thediabzen.com/index.php/d/article/view/60.